Overview of Urirex K

Property	Description
Active ingredients	Hydrochlorothiazide, Potassium Chloride
Form	Solid oral dosage form (e.g., tablet)
Pharmacological class	Thiazide Diuretic & Electrolyte Supplement
Common use	Fluid and mineral balance support
Origin	Synthetic derivative (HCTZ) & Essential mineral salt (KCl)

What is Urirex K and What Type of Medicine Is It?

Urirex K is a prescription-only, fixed-dose combination product supplied as a solid oral dosage form. It is classified primarily as a thiazide diuretic and an electrolyte supplement. The combined formulation, merging a diuretic with potassium, is clinically recognized for its balanced approach to managing fluid volume. The active component Hydrochlorothiazide is a diuretic and an antihypertensive agent. This classification confirms that the medicine’s primary action is to reduce excess fluid volume.

Composition and Origin: The Dual Active Ingredients

The medicine’s composition consists of two active ingredients: Hydrochlorothiazide and Potassium Chloride. Hydrochlorothiazide is a synthetic derivative stemming from the sulfonamide group of chemical compounds, while Potassium Chloride is an essential mineral salt. This combination is intentional, merging a compound that promotes fluid loss with a compound that simultaneously replenishes the essential potassium ion. This strategy directly counters the electrolyte loss that is commonly associated with diuretic use.

General Purpose: How Urirex K Supports Fluid and Mineral Balance

The general purpose of Urirex K is to support the body in achieving fluid reduction while simultaneously preserving necessary electrolyte balance. The diuretic component promotes the excretion of excess sodium and water from the body. Because most diuretics can cause the loss of natural potassium, the inclusion of Potassium Chloride directly supplies this mineral, which is necessary for maintaining proper intracellular tonicity and the transmission of nerve impulses. This dual function provides a balanced strategy for managing fluid and mineral homeostasis, distinguishing it from single-agent diuretics used for fluid management.

Regulatory References

Potassium Role in the Body (NIH)

What side effects are possible with Urirex K?

Possible Side Effects and Safety Information

This information describes the documented safety profile of Urirex K as published in official government regulatory sources, focusing on adverse reactions and conditions that restrict its use.

Serious Adverse Reactions

The most clinically significant adverse reaction associated with the use of this medicine is Hyperkalemia (high blood potassium). This condition can be life-threatening as it may lead to severe neuromuscular or cardiac issues, including cardiac arrhythmias, muscle weakness, and, in rare instances, cardiac arrest or death.

Serious adverse effects have also been documented within the gastrointestinal system, including Stenotic or Ulcerative Lesions of the small bowel or upper gastrointestinal bleeding. These localized effects are specific to the solid oral dosage form.

Other Adverse Reactions and Safety Restrictions

Less severe, common adverse events reported through postmarketing surveillance primarily involve minor gastrointestinal disturbances, such as nausea, vomiting, abdominal discomfort, or loose bowel movements. The frequency of these events is not precisely classified but represents general clinical experience.

Safety documents list specific conditions that Contraindicate (strictly prohibit) the use of Urirex K, as they dramatically increase the risk of severe complications. These conditions include pre-existing Hyperkalemia, active peptic ulcer disease, existing gastrointestinal obstruction, and simultaneous use with potassium-sparing diuretics.

Population-Specific Considerations

Patients with impaired potassium excretion mechanisms, such as those with acute or chronic renal insufficiency or severe myocardial damage, are identified as being at a significantly greater risk for developing severe, life-threatening Hyperkalemia. Regulatory documents emphasize the need for regular monitoring of serum potassium levels when the medicine is used in appropriate populations.

Overdose and Emergency Response

The official regulatory profile for Urirex K overdose is characterized by severe consequences stemming from acute volume depletion and critical electrolyte shifts due to excessive exposure to Hydrochlorothiazide and Potassium Chloride.

Documented manifestations of overdose may include signs of fluid loss such as severe thirst, generalized weakness, dizziness, and fainting (orthostatic hypotension), along with nausea and vomiting. Electrolyte imbalance (hyperkalemia or hyponatremia) can lead to confusion, severe muscular fatigue, listlessness, and changes in heart rate.

The most severe documented outcomes involve cardiovascular and neurological compromise. These risks include life-threatening cardiac dysrhythmias, potentially leading to cardiac arrest, primarily associated with severe hyperkalemia. Other officially listed severe outcomes include seizures, acute kidney injury from volume depletion, and the rare risk of acute angle-closure glaucoma. No specific antidote is known; treatment is symptomatic and supportive.

When to Seek Immediate Medical Help

In all cases of suspected overdose, regulatory documents mandate that the patient must seek immediate medical attention. Emergency services must be contacted immediately if symptoms such as severe hypotension, loss of consciousness, or signs of cardiac irregularity occur. Hospital monitoring is required to manage critical fluid and electrolyte imbalances and provide symptomatic support.

Therapeutic Uses of Urirex K

The primary therapeutic domain of Urirex K, which contains the active ingredient potassium citrate, is relevant for easing symptoms linked to organ-specific functional stress in the renal system. This product is commonly used to help manage conditions characterized by periods of heightened symptoms related to kidney stones.

Potassium citrate is indicated for the management of three types of conditions: Hypocitraturic calcium oxalate nephrolithiasis, Renal Tubular Acidosis (RTA) with calcium stones, and Uric acid lithiasis with or without calcium stones. This is often used during phases when symptoms become more noticeable.

This application helps address symptom clusters that may become intense or disruptive. It is relevant across domains where additional symptomatic support is needed, thereby supporting patients during episodes of heightened discomfort and providing support that helps ease the overall symptom burden. As one aspect of its benefit, “it provides supportive relief when symptoms interfere with routine activities.”

Quick Fact: Relief for Physiological Strain

Regulatory References

NIH DailyMed official labeling for Potassium Citrate Extended-Release Tablets

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Urirex K?

The population eligibility for Urirex K (Potassium Citrate) is strictly defined by regulatory authorities to manage risk, primarily concerning potassium balance and gastrointestinal integrity. Official labeling establishes absolute exclusions and specific restrictions based on patient status.

Contraindicated Populations

Urirex K must not be used by individuals with Hyperkalemia (elevated potassium levels) or conditions that predispose to it, such as chronic renal failure or uncontrolled diabetes mellitus. The medicine is also contraindicated in patients with a Glomerular Filtration Rate (GFR) below 0.7 mL/kg/min and in those with Peptic Ulcer Disease or conditions that cause a delay in tablet passage through the GI tract [e.g., intestinal obstruction or concomitant use of anticholinergic medication].

️ Restricted and Age-Group Use

Use should be avoided in patients with severe myocardial damage or heart failure. The regulatory status for children is limited: safety and effectiveness have not been established in pediatric patients. For pregnant and lactating patients, the medicine is Pregnancy Category C, meaning it is only permitted if clearly needed after careful consideration.

What should I know about interactions with other medicines?

Urirex K Interactions with other medicines and products

This section outlines interactions with other medicines and products as officially documented in government regulatory prescribing information for Urirex K (Hydrochlorothiazide and Potassium Chloride).

Formal Interaction Restrictions

Classification	Interacting Substance(s)	Documented Constraint
Contraindicated	Potassium-Sparing Diuretics (e.g., Triamterene, Amiloride)	Avoid concomitant use due to high risk of severe hyperkalemia.
Contraindicated	Aliskiren (in dual RAAS blockade)	Contraindicated in patients with diabetes when used with the HCTZ component.
Generally Not Recommended	Lithium	The HCTZ component reduces the renal clearance of Lithium, leading to a high risk of toxicity.

Interactions Affecting Clearance and Timing

Bile Acid Sequestrants: Absorption of Hydrochlorothiazide is significantly reduced by Cholestyramine and Colestipol Resins. To manage this pharmacokinetic interaction, HCTZ must be taken at least 1 hour before or 4 to 6 hours after the resin.
Parathyroid Function Testing: The HCTZ component necessitates discontinuation of the medicine before carrying out tests for parathyroid function due to documented interference with results.

Pharmacodynamic and Potentiating Interactions

Other Antihypertensive Agents: An additive or potentiating effect on blood pressure lowering may occur.
NSAIDs: Non-Steroidal Anti-Inflammatory Drugs can reduce the diuretic, natriuretic, and antihypertensive effects of HCTZ.
Alcohol, Barbiturates, or Narcotics: These substances can potentiate the effects of HCTZ, increasing the risk of orthostatic hypotension.
Corticosteroids/ACTH: Co-administration results in intensified electrolyte depletion, specifically hypokalemia.

Population-Specific Notes

The Hydrochlorothiazide component's exposure (AUC) is increased in elderly patients. Antidiabetic drug regimens may require adjustment due to the HCTZ component.

Mechanism of Action

How Urirex K Works: Mechanism of Action

Urirex K's physiological effect results from the coordinated action of its two components on distinct mechanistic domains: Targeted Salt Transport Blockade and Essential Mineral Homeostasis.

Targeted Renal Salt Transport Blockade

The mechanism is initiated by Hydrochlorothiazide acting as a direct inhibitor of the Sodium Chloride Cotransporter (NCC) in the kidney's distal convoluted tubule. This molecular blockade prevents the reabsorption of Na^+ and Cl^- ions back into the bloodstream, creating an osmotic gradient within the tubule. Water passively follows this retained salt, leading to the core physiological effect of diuresis (increased fluid excretion) and a subsequent reduction in the body’s overall fluid volume.

Essential Mineral Homeostasis and Mechanistic Synergy

As a secondary consequence of the diuretic action, the increased Na^+ delivered to the final segments of the nephron enhances the compensatory excretion of the potassium ion ( K^+). The second component, Potassium Chloride, replenishes the lost K^+, thereby maintaining the electrochemical gradients essential for regulating the membrane potential of excitable tissues. This synergy addresses the K^+ loss caused by the diuretic action, sustaining the K^+ concentration required for these cellular processes.

Dosage and Administration Information

Urirex K is administered by the oral route as a solid extended-release tablet. The official administration protocol requires the tablet to be taken with meals or within thirty minutes following a meal or a bedtime snack. This administration timing is a critical instruction intended to mitigate the potential for localized gastrointestinal irritation associated with the oral administration of potassium salts. Furthermore, the tablets must be swallowed whole and should not be crushed, chewed, or sucked, as this would compromise the intended extended-release mechanism of the formulation.

The standard labeled regimen for adults establishes an initial daily dose ranging from 30 mEq to 60 mEq, which is administered in divided doses throughout the day, typically either twice or three times daily. The precise initial dosage is determined by the patient's baseline urinary citrate excretion, with the higher range used for severe hypocitraturia (urinary citrate <150 mg/day). The total daily dosage must not exceed the maximum of 100 mEq.

The usage of this medication follows a titration protocol guided by specific laboratory measurements. Dosing is adjusted systematically until the 24-hour urinary citrate level increases to a therapeutic range and the urinary pH is maintained between 6.0 and 7.0, defining the course duration by clinical response. A key procedural constraint for initiating the oral regimen is the confirmation that the patient's serum potassium concentration is 2.5 mEq/L or greater. Official labeling does not establish specific dosing recommendations for the pediatric population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Urirex K

The information below summarizes the research structure and the observations reported in studies concerning the components of Urirex K. The findings described represent group patterns observed during the trials and are not predictions for any individual's experience.

Evidence for Managing Conditions Characterized by Kidney Stone Formation

Research has explored the use of the potassium citrate component in individuals with the indicated conditions of hypocitraturia and certain forms of lithiasis (stone formation). The primary study designs included Randomized Controlled Trials (RCTs) and retrospective reviews. Researchers monitored urinary chemical markers, such as pH levels and the concentration of citrate and calcium in the urine, and the rate of new stone formation. Findings describe patterns observed where research measured shifts in these levels and report how recurrence rates evolved in the observed populations.

Evidence for Supporting Fluid Reduction and Electrolyte Balance

The hydrochlorothiazide and potassium chloride components were studied for temporary physiological imbalance in adults with hypertension using large RCTs and systematic reviews. The main outcomes researchers monitored included changes in blood pressure (BP) levels and the balance of serum electrolytes. Studies reported measured changes in BP levels. Trials monitored serum potassium concentrations and noted how they compared to the diuretic component alone. Research also examined long-term outcomes, focusing on patterns related to major cardiovascular events.

Long-Term Research and Extended Follow-up

For both indications, studies have explored responses over defined time intervals, providing intermediate-term data. Long-term outcomes are not fully established for all aspects of therapy. Research is ongoing to explore how measured changes evolved over time, as long-term data for specific combination products may be limited.

Research Gaps and Remaining Uncertainties

Data for certain pediatric or pregnant populations remain insufficient. A key uncertainty is that comparative evidence is lacking in some areas, particularly direct, large-scale randomized controlled trials comparing this specific fixed-dose product against every other possible therapeutic option. Research is ongoing regarding the full profile of metabolic changes over extended periods.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Urirex K (FAQ)

Q: What are the most common side effects reported by people taking Urirex K?

According to official product information, the most common side effects reported are related to the digestive system. These include minor gastrointestinal disturbances such as nausea, vomiting, stomach pain/discomfort, or loose bowel movements. If severe or persistent stomach issues occur, consulting a healthcare professional is generally recommended.

Q: Is a metallic or waxy feeling in the stool normal when taking Urirex K extended-release tablets?

Official information for extended-release potassium products indicates that it is an expected and harmless effect to see the empty tablet or capsule shell (sometimes described as waxy or metallic-looking) in the stool. The medication is designed to be released as the shell passes through the digestive tract, and the empty shell is passed out of the body.

Q: Are there any specific food or drinks to avoid while taking Urirex K?

Regulatory documents suggest that individuals taking this medication should avoid using salt substitutes that contain potassium, unless specifically directed otherwise by their healthcare provider. This is to manage the increased risk of developing elevated potassium levels in the blood (hyperkalemia).

Q: Does Urirex K interact with other supplements or herbal products?

Based on official prescribing information, there is a particular concern regarding other potassium sources. Patients should avoid taking additional potassium-containing supplements or salt substitutes because of the risk of developing severe or life-threatening hyperkalemia (high potassium levels).

Q: Can taking Urirex K affect my blood pressure readings?

Yes, Urirex K is a combination medicine, and the hydrochlorothiazide component is classified as an antihypertensive agent (a medicine that lowers blood pressure). Therefore, official labeling notes that it may have an additive or potentiating effect on blood pressure lowering, especially when used with other antihypertensive medications.

Q: If I miss a dose of Urirex K, what is the general guidance?

Official guidance states that if a dose is missed, it is generally advised that it be taken as soon as a person remembers. However, if it is almost time for the next scheduled dose, the person should skip the missed dose and take only the next regularly scheduled dose. Double or extra doses should not be taken.

Q: Is it normal to see part of the tablet shell in the stool?

Yes, it is common to see pieces of the extended-release tablet or the empty shell in the stool. Regulatory documents reassure patients that this is normal and not a cause for concern, as the medication itself has already been absorbed into the system.

Q: What is the purpose of the extended-release formulation of Urirex K?

The purpose of the extended-release formulation is to allow the medication to be released slowly into the body over time. This controlled release is important because it reduces the concentration of potassium in the gastrointestinal tract, which helps to prevent localized irritation and potential serious side effects.

Q: Can Urirex K cause any changes in heart rhythm?

Regulatory warnings indicate that Urirex K carries a risk of Hyperkalemia (high potassium levels). A severe increase in potassium can be life-threatening and may lead to serious cardiac arrhythmias (irregular heartbeat) or even cardiac arrest. Due to this risk, the patient's potassium levels are typically monitored regularly by a healthcare professional.

Q: Does Urirex K affect blood sugar levels, especially for people with diabetes?

Yes, official labeling notes that the hydrochlorothiazide component of the medicine may interfere with the body's control of blood glucose. This action can reduce the effectiveness of insulin or other diabetic medicines, and the antidiabetic regimen may need re-evaluation by the prescribing physician.

Q: What happens if Urirex K is taken without food?

Official prescribing instructions caution that the tablets should not be taken on an empty stomach. Taking the medicine without food or a snack is discouraged because it significantly increases the potential for gastric irritation and the risk of serious problems like lesions in the gastrointestinal system.

Q: Why is hydration an important factor when taking Urirex K?

Because this medicine contains a diuretic component, it is important to maintain fluid balance. According to patient information, drinking extra fluids is often recommended to increase urine output, which helps to promote optimal kidney function and supports the therapeutic goals of the medication.

Q: Are there any known issues with swallowing or the tablets getting 'stuck' in the throat?

Official product warnings note that some patients have reported a sensation of the tablet getting stuck in the throat. This must be taken seriously, as it can be a symptom of a serious stomach or esophageal problem. If this sensation occurs, seeking immediate evaluation from a healthcare provider is important.

Q: What signs indicate that Urirex K might be irritating the stomach or esophagus?

The regulatory documents list several serious signs of irritation. These include severe stomach or abdominal pain, difficulty or pain with swallowing, passing black or tarry stools, or vomit that looks like coffee grounds. Experiencing any of these symptoms warrants seeking immediate medical attention.

Q: Does Urirex K influence the risk of developing gout?

Yes, official warnings for the hydrochlorothiazide component state that it can decrease the body's excretion of uric acid. This can lead to increased serum urate levels, which is a known risk factor and potential trigger for attacks of gout.

Q: Is Urirex K associated with any skin reactions or rashes?

The hydrochlorothiazide component of Urirex K is known to cause increased sensitivity to sunlight (photosensitivity). Official warnings indicate that this can increase the risk of severe sunburn and other dermatological reactions when exposed to the sun.

Q: Does Urirex K interact with any common antacids?

Official product information suggests a potential interaction with aluminum-containing antacids when used with the citrate form of the drug. Taking these at the same time may result in increased absorption of aluminum, and changes in dosing schedule may be necessary as determined by a healthcare provider.

How should Urirex K be stored and disposed of?

How to Store and Dispose of Urirex K

Storage of Urirex K (Hydrochlorothiazide and Potassium Chloride) must comply with controlled conditions to maintain stability and effectiveness. The product must be stored at controlled room temperature, typically 20 C to 25 C. It is mandatory to keep the tablets away from excess heat, moisture, and direct light, and strictly prevent the product from freezing.

Container and Protection

Store the medication in its original container, ensuring it is tightly closed. For safety, Urirex K must be kept out of the reach of children. Do not keep outdated or unused medicine. Disposal instructions require patients to consult a healthcare professional for guidance on discarding the product according to local pharmaceutical waste regulations.

Urirex K